PrP106-126 (Human) [6495]



PrP106-126 (Human)


SMILES CSCC[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)C(C)C)C(C)C
InChIKey XPZWWTIIKSODDO-MBNDGZRNSA-N
Sequence KTNMKHMAGAAAAGAVVGGLG
HELM PEPTIDE1{K.T.N.M.K.H.M.A.G.A.A.A.A.G.A.V.V.G.G.L.G}$$$$

Chemical Properties

Hydrogen bond acceptors 29
Hydrogen bond donors 27
Rotatable bonds 64
Log P -10.285
Molecular weight (Da) 1911.0
Stereochemistry info partial

Database connections

Model (AF2) FPR2/ALX


Bioactivities

Receptor Activity Source
Protein Gene Species Family Class Type Min Avg Max Database
Receptor Activity Source
Protein Gene Species Family Class Type Min Avg Max Database

PrP106-126 (Human)


Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections

Model (AF2) FPR2/ALX


Compound is not listed as a drug.